Virginia Tech Carilion School of Medicine; Roanoke, VA, USA.
Section of Dermatology and Mohs Surgery, Department of Internal Medicine, Carilion Clinic; Roanoke, VA, USA.
Skin Therapy Lett. 2021 Mar;26(2):6-8.
Human papillomavirus (HPV)-induced cutaneous disease is a common complaint for patients presenting for dermatology evaluation. Infection by HPV is the major etiologic factor in the development of cutaneous warts, epidermodysplasia verruciformis, and possibly a subset of cutaneous squamous cell carcinoma. Carcinoma of the genitourinary tract, most notably cervical carcinoma, is the most severe manifestation of infection with specific serotypes of HPV. For this reason, the HPV immunization (Gardasil) was developed in 2006 and upgraded in 2018 to a nonavalent formulation that includes serotypes 6, 11, 16, 18, 31, 33, 45, 52, 58. While immunization is highly effective at preventing infection with serotypes included in the formulation, it is less clear if the immunization can aid in managing active HPV infection. This review examines the available literature regarding the role of HPV immunization in managing common warts, genital warts, keratinocyte carcinoma, and epidermodysplasia verruciformis.
人乳头瘤病毒（HPV）引起的皮肤疾病是皮肤科就诊患者常见的主诉。HPV 感染是皮肤疣、疣状表皮发育不良和某些皮肤鳞状细胞癌发展的主要病因。生殖道癌，尤其是宫颈癌，是 HPV 特定血清型感染的最严重表现。出于这个原因，HPV 疫苗（加德西）于 2006 年开发，并于 2018 年升级为九价疫苗，其中包括血清型 6、11、16、18、31、33、45、52、58。虽然疫苗接种在预防疫苗配方中包含的血清型感染方面非常有效，但疫苗接种是否有助于治疗 HPV 感染尚不清楚。本综述检查了有关 HPV 疫苗接种在治疗常见疣、生殖器疣、角质形成细胞癌和疣状表皮发育不良方面作用的现有文献。
